News
We send the latest information from SMC Laboratories.
SMC announces Announcement of webinar 【High quality non-clinical study designs】
Today we are excited to invite you to join our Online Linkedin Webinar that will be taking place next week on January 19th (JST) from 10:30 AM. In this webinar series we have being looking at examples of both clinical NASH trials as well as non-clinical study designs. For the 3rd installment in this…
NASH, the fastest growing cause of liver cancer
We wish you a Happy and Prosperous New Year! If you are currently planning to begin a project this year, we would love to support you in any way we can, including conducting one of our high quality pharmacology studies. Today, we would like to share with you a little bit about the…
SMC to attend Japan-UK Virtual Partnering!
We are pleased to announce that SMC Laboratories will be participating in the Japan-UK Virtual Partnering Online Event from January 23rd (Mon) to February 13th (Mon). The Japan-UK Virtual Partnering Online Event is organized by the Osaka Prefectural Government, and offers companies, start-ups and research institutions in Japan and the UK the opportunity to…
Fibrosis is involved in many diseases and disease-related deaths
Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments that target fibrosis. Fibrosis is involved in many diseases, so even if fibrosis is not your direct target, please read on. Fibrosis can occur in many different organs. It is caused by a disruption in the wound healing…
Study on the efficacy of dietary supplements in the STAM™ model published in Cell Death & Disease.
SMC is proud to announce that J2H biotech (KOR) has published the results of their study using our pre-clinical services with STAM™ model in Cell Death & Disease. Title: Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH (Lee et al., Cell Death Dis . 2022) This…
Introduction of STAM™ model for pre-clinical studies for liver cancer
Today, we give you a brief introduction to our proprietary NASH-HCC model (STAM™ model). The STAM™ model was originally developed as a NASH model, but with a 100% incidence of hepatocellular carcinoma (HCC) as early as 20 weeks of age, it is also an excellent platform for oncology research and therapeutic development. The model…
Study on the efficacy of dietary supplements in the STAM™ model published in BMJ Open Gastroenterology
SMC is proud to announce that GN Corporation Co. Ltd (JPN) has published the results of their study using our STAM™ model in BMJ Open Gastroenterology. In this study, the authors observed how two β-glucans derived from the AFO-202 and N-163 strains of black yeast, Aureobasidium pullulans, affected the gut microbiota and fecal metabolome…
Drug Efficacy Study in the STAM™ Model Published in Biomedicines.
SMC is proud to announce that MRM Health (BEL) has published the results of their study using our STAM™ model in Biomedicines. ■Title A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo (Pinheiro et al., Biomedicines. 2022) The above study tested the therapeutic effects of a…
Introducing our new skin disease model: Imiquimod (IMQ)-induced psoriasis model
We are pleased to announce that we have expanded our preclinical model lineup by including the “Imiquimod (IMQ)-induced dermatitis model” for psoriasis. Psoriasis is a refractory skin disease that is caused by both genetic and environmental factors. It causes chronic inflammation characterized by the clinical appearance of erythema and scaling of the skin….
Introduction of MAFLD criteria and the disease model
Today, we would like to introduce metabolic dysfunction-associated fatty liver disease (MAFLD), a new concept in the study of fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is defined as the presence of fatty liver disease in the absence of any known causes of steatosis. The number of NAFLD cases are growing worldwide due…